阿哌沙班与阿司匹林在全髋或全膝关节置换术后静脉血栓栓塞预防中的效果与并发症比较
本研究基于研究网络数据,比较2018至2023年初次全髋或全膝关节置换术后仅用阿司匹林(81或325 mg,每日两次)或仅用阿哌沙班(2.5 mg,每日两次)预防静脉血栓栓塞的患者。结果显示,与阿司匹林相比,阿哌沙班与术后90天内血栓事件及出血并发症的 odds 升高相关。
要点
- 全髋置换术后用阿哌沙班者深静脉血栓、肺栓塞、输血、关节积血、心肌梗死和再入院 odds 均高于用阿司匹林者。
- 全膝置换术后用阿哌沙班者深静脉血栓、肺栓塞、输血、关节积血、心肌梗死、卒中和再入院 odds 均高于用阿司匹林者。
- 作者认为该结果提示阿哌沙班潜在风险,在缺乏标准化临床指南时需用数据指导患者管理。
核心结论
- 与阿司匹林相比,阿哌沙班与全髋和全膝关节置换术后血栓事件及出血并发症的 odds 升高相关。
研究设计与样本
- 利用研究网络,按 Current Procedural Terminology 和国际疾病分类第十版代码检索2018至2023年接受全髋或全膝关节置换术的患者。
- 患者分为仅用阿司匹林(81或325 mg,每日两次)或仅用阿哌沙班(2.5 mg,每日两次)预防静脉血栓栓塞的队列。
- 计算 odds 比及95%置信区间,采用卡方分析检验差异,双侧 alpha 值<0.05 定义为统计学显著。
主要发现
- 全髋置换术后用阿哌沙班者术后90天内深静脉血栓 odds 比为5.22(95%CI 4.60至5.93),肺栓塞为7.85(6.55至9.41),输血为1.5(1.27至1.81),关节积血为1.87(1.26至2.24),心肌梗死为1.12(1.03至1.23),再入院为1.18(1.09至1.28)。
- 全膝置换术后用阿哌沙班者术后90天内深静脉血栓 odds 比为4.57(95%CI 4.15至5.02),肺栓塞为6.05(5.33至6.88),输血为1.6(1.36至1.96),关节积血为1.48(1.03至2.12),心肌梗死为1.42(1.29至1.63),卒中为1.16(1.09至1.53),再入院为1.84(1.61至2.11)。
关键数值与推荐
- 阿司匹林剂量为81或325 mg,每日两次;阿哌沙班剂量为2.5 mg,每日两次。
- 统计学显著性定义为双侧 alpha 值<0.05。
临床怎么用
- 作者认为,该结果提示阿哌沙班潜在风险,在缺乏标准化临床指南时需用数据指导患者管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major orthopaedic procedures, such as total hip arthroplasty (THA) and total knee arthroplasty (TKA), carry risk for thrombotic complications. To reduce the incidence of postoperative venous thromboembolism (VTE), surgical patients are often prescribed antiplatelet or anticoagulant treatment. The objective of this study was to compare rates of VTE events and complications between apixaban and aspirin for VTE prophylaxis following primary THA and TKA. METHODS: We searched a research network using Current Procedural Terminology and International Classification of Diseases, Tenth Revision codes for patients who underwent a THA or TKA from 2018 to 2023. Patients were then categorized into cohorts of patients who received only aspirin (81 or 325 mg, twice daily) or patients who received only apixaban (2.5 mg, twice daily) for VTE prophylaxis. Odds ratios with 95% confidence intervals were calculated to compare the associations of selected prophylaxis with VTE events and complications, and Chi-square analyses were performed to determine the significance of differences. Statistical significance was defined as a two-sided alpha value < 0.05. RESULTS: Patients who received apixaban after THA had increased odds of deep vein thrombosis (5.22, 4.60 to 5.93), pulmonary embolism (7.85, 6.55 to 9.41), transfusion (1.5, 1.27 to 1.81), hemarthrosis (1.87, 1.26 to 2.24), myocardial infarction (1.12, 1.03 to 1.23), and readmission (1.18, 1.09 to 1.28) within 90 days after surgery. Patients who received apixaban after TKA had increased odds of deep vein thrombosis (4.57, 4.15 to 5.02), pulmonary embolism (6.05, 5.33 to 6.88), transfusion (1.6, 1.36 to 1.96), hemarthrosis (1.48, 1.03 to 2.12), myocardial infarction (1.42, 1.29 to 1.63), stroke (1.16, 1.09 to 1.53), and readmission (1.84, 1.61 to 2.11) within 90 days after TKA. CONCLUSIONS: Apixaban is associated with increased odds of thrombotic events and bleeding complications in the postoperative period of THA and TKA compared to aspirin. This highlights the potential risks associated with apixaban use and the importance of using data to guide patient management in the absence of standardized clinical guidelines.
引用
- Chokshi SN, Gay SS, Barimani B, et al. Effects and Complications of Apixaban versus Aspirin for Venous Thromboembolism Prophylaxis after Total Hip or Knee Arthroplasty. J Arthroplasty. 2025. PMID: 40158751. doi:10.1016/j.arth.2025.03.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。